Biotech Stocks Surge to 52-Week Highs on Strong Clinical Data
Several biotech stocks reached new 52-week highs on October 5, 2026, propelled by positive clinical research data and strong Phase 3 results. Vaxcyte Inc. (PCVX) saw a significant jump of 31%, while INFU and ILMN rose 7%, CRL gained 7%, and HTFL increased by 5%.
SAN DIEGO (dpa-AFX) - The following biotech stocks reached a 52-week high on October 5, 2026, driven by key catalysts such as encouraging clinical research data. Vaxcyte Inc. (PCVX) was among the biotech names hitting that 52-week high. Vaxcyte is a clinical-stage vaccine innovation company developing broad-spectrum conjugate and protein vaccines.